Determination of breast cancer prognosis after neoadjuvant chemotherapy: comparison of Residual Cancer Burden (RCB) and Neo-Bioscore

To compare RCB (Residual Cancer Burden) and Neo-Bioscore in terms of prognostic performance and see if adding pathological variables improve these scores. We analysed 750 female patients with invasive breast cancer (BC) treated with neoadjuvant chemotherapy (NAC) at Institut Curie between 2002 and 2...

Full description

Saved in:
Bibliographic Details
Published in:British journal of cancer 2021-04, Vol.124 (8), p.1421-1427
Main Authors: Laas, Enora, Labrosse, Julie, Hamy, Anne-Sophie, Benchimol, Gabriel, de Croze, Diane, Feron, Jean-Guillaume, Coussy, Florence, Balezeau, Thomas, Guerin, Julien, Lae, Marick, Pierga, Jean-Yves, Reyal, Fabien
Format: Article
Language:English
Subjects:
Antineoplastic Agents - therapeutic use
Breast cancer
Breast Neoplasms - drug therapy
Breast Neoplasms - pathology
Chemotherapy
Female
Humans
Invasiveness
Medical prognosis
Middle Aged
Neoadjuvant Therapy - methods
Neoplasm Staging
Neoplasm, Residual
Population
Prognosis
Survival Analysis
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c430t-53717e36ccd5f2b09c141fc3670f9b0f9d62c59ddf89e723a17dda8034ec27643
cites cdi_FETCH-LOGICAL-c430t-53717e36ccd5f2b09c141fc3670f9b0f9d62c59ddf89e723a17dda8034ec27643
container_end_page 1427
container_issue 8
container_start_page 1421
container_title British journal of cancer
container_volume 124
creator Laas, Enora
Labrosse, Julie
Hamy, Anne-Sophie
Benchimol, Gabriel
de Croze, Diane
Feron, Jean-Guillaume
Coussy, Florence
Balezeau, Thomas
Guerin, Julien
Lae, Marick
Pierga, Jean-Yves
Reyal, Fabien
description To compare RCB (Residual Cancer Burden) and Neo-Bioscore in terms of prognostic performance and see if adding pathological variables improve these scores. We analysed 750 female patients with invasive breast cancer (BC) treated with neoadjuvant chemotherapy (NAC) at Institut Curie between 2002 and 2012. Scores were compared in global population and by BC subtype using Akaike information criterion (AIC), C-Index (concordance index), calibration curves and after adding lymphovascular invasion (LVI) and pre-/post-NAC TILs levels. RCB and Neo-Bioscore were significantly associated to disease-free and overall survival in global population and for triple-negative BC. RCB had the lowest AICs in every BC subtype, corresponding to a better prognostic performance. In global population, C-Index values were poor for RCB (0.66; CI [0.61-0.71]) and fair for Neo-Bioscore (0.70; CI [0.65-0.75]). Scores were well calibrated in global population, but RCB yielded better prognostic performances in each BC subtype. Concordance between the two scores was poor. Adding LVI and TILs improved the performance of both scores. Although RCB and Neo-Bioscore had similar prognostic performances, RCB showed better performance in BC subtypes, especially in luminal and TNBC. By generating fewer prognostic categories, RCB enables an easier use in everyday clinical practice.
doi_str_mv 10.1038/s41416-020-01251-3
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8039034</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2510999312</sourcerecordid><originalsourceid>FETCH-LOGICAL-c430t-53717e36ccd5f2b09c141fc3670f9b0f9d62c59ddf89e723a17dda8034ec27643</originalsourceid><addsrcrecordid>eNpdkU1rHSEUhiW0JLdp_0AWQegmXdj4MTOOXQRybz8htBDatXj1TK6XGZ3oTCD7_vCaThraLkTE5zz4-iJ0wuhbRkV7nitWsYZQTgllvGZEHKAVqwUnrOXyGVpRSiWhitMj9CLnfTkq2spDdCREXbeSsRX6-R4mSIMPZvIx4NjhbQKTJ2xNsJDwmOJNiNlnbLoC4gDRuP18Z0JBdjDEaQfJjPfvsI3DaJLPi-Uasnez6fFm8azn5CDgs-vN-g02weGvEMnax2xjgpfoeWf6DK8e92P04-OH75vP5Orbpy-byytiK0EnUgvJJIjGWld3fEuVLfk7KxpJO7UtyzXc1sq5rlUguTBMOmdaKiqwXDaVOEYXi3ectwM4C2FKptdj8oNJ9zoar_-9CX6nb-KdLg5VNEVw9ihI8XaGPOnBZwt9b8q_zFnzqpWyUkrIgr7-D93HOYUST5eqqCoQ44XiC2VTzDlB9_QYRvVDyXopWZeS9e-StShDp3_HeBr506r4BZSOpGU</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2510999312</pqid></control><display><type>article</type><title>Determination of breast cancer prognosis after neoadjuvant chemotherapy: comparison of Residual Cancer Burden (RCB) and Neo-Bioscore</title><source>PubMed (Medline)</source><source>Springer Link</source><creator>Laas, Enora ; Labrosse, Julie ; Hamy, Anne-Sophie ; Benchimol, Gabriel ; de Croze, Diane ; Feron, Jean-Guillaume ; Coussy, Florence ; Balezeau, Thomas ; Guerin, Julien ; Lae, Marick ; Pierga, Jean-Yves ; Reyal, Fabien</creator><creatorcontrib>Laas, Enora ; Labrosse, Julie ; Hamy, Anne-Sophie ; Benchimol, Gabriel ; de Croze, Diane ; Feron, Jean-Guillaume ; Coussy, Florence ; Balezeau, Thomas ; Guerin, Julien ; Lae, Marick ; Pierga, Jean-Yves ; Reyal, Fabien</creatorcontrib><description>To compare RCB (Residual Cancer Burden) and Neo-Bioscore in terms of prognostic performance and see if adding pathological variables improve these scores. We analysed 750 female patients with invasive breast cancer (BC) treated with neoadjuvant chemotherapy (NAC) at Institut Curie between 2002 and 2012. Scores were compared in global population and by BC subtype using Akaike information criterion (AIC), C-Index (concordance index), calibration curves and after adding lymphovascular invasion (LVI) and pre-/post-NAC TILs levels. RCB and Neo-Bioscore were significantly associated to disease-free and overall survival in global population and for triple-negative BC. RCB had the lowest AICs in every BC subtype, corresponding to a better prognostic performance. In global population, C-Index values were poor for RCB (0.66; CI [0.61-0.71]) and fair for Neo-Bioscore (0.70; CI [0.65-0.75]). Scores were well calibrated in global population, but RCB yielded better prognostic performances in each BC subtype. Concordance between the two scores was poor. Adding LVI and TILs improved the performance of both scores. Although RCB and Neo-Bioscore had similar prognostic performances, RCB showed better performance in BC subtypes, especially in luminal and TNBC. By generating fewer prognostic categories, RCB enables an easier use in everyday clinical practice.</description><identifier>ISSN: 0007-0920</identifier><identifier>EISSN: 1532-1827</identifier><identifier>DOI: 10.1038/s41416-020-01251-3</identifier><identifier>PMID: 33558711</identifier><language>eng</language><publisher>England: Nature Publishing Group</publisher><subject>Antineoplastic Agents - therapeutic use ; Breast cancer ; Breast Neoplasms - drug therapy ; Breast Neoplasms - pathology ; Chemotherapy ; Female ; Humans ; Invasiveness ; Medical prognosis ; Middle Aged ; Neoadjuvant Therapy - methods ; Neoplasm Staging ; Neoplasm, Residual ; Population ; Prognosis ; Survival Analysis ; Treatment Outcome</subject><ispartof>British journal of cancer, 2021-04, Vol.124 (8), p.1421-1427</ispartof><rights>The Author(s), under exclusive licence to Cancer Research UK 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>The Author(s), under exclusive licence to Cancer Research UK 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c430t-53717e36ccd5f2b09c141fc3670f9b0f9d62c59ddf89e723a17dda8034ec27643</citedby><cites>FETCH-LOGICAL-c430t-53717e36ccd5f2b09c141fc3670f9b0f9d62c59ddf89e723a17dda8034ec27643</cites><orcidid>0000-0002-9416-5601 ; 0000-0002-2318-3589</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8039034/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8039034/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,315,733,786,790,891,27957,27958,53827,53829</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33558711$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Laas, Enora</creatorcontrib><creatorcontrib>Labrosse, Julie</creatorcontrib><creatorcontrib>Hamy, Anne-Sophie</creatorcontrib><creatorcontrib>Benchimol, Gabriel</creatorcontrib><creatorcontrib>de Croze, Diane</creatorcontrib><creatorcontrib>Feron, Jean-Guillaume</creatorcontrib><creatorcontrib>Coussy, Florence</creatorcontrib><creatorcontrib>Balezeau, Thomas</creatorcontrib><creatorcontrib>Guerin, Julien</creatorcontrib><creatorcontrib>Lae, Marick</creatorcontrib><creatorcontrib>Pierga, Jean-Yves</creatorcontrib><creatorcontrib>Reyal, Fabien</creatorcontrib><title>Determination of breast cancer prognosis after neoadjuvant chemotherapy: comparison of Residual Cancer Burden (RCB) and Neo-Bioscore</title><title>British journal of cancer</title><addtitle>Br J Cancer</addtitle><description>To compare RCB (Residual Cancer Burden) and Neo-Bioscore in terms of prognostic performance and see if adding pathological variables improve these scores. We analysed 750 female patients with invasive breast cancer (BC) treated with neoadjuvant chemotherapy (NAC) at Institut Curie between 2002 and 2012. Scores were compared in global population and by BC subtype using Akaike information criterion (AIC), C-Index (concordance index), calibration curves and after adding lymphovascular invasion (LVI) and pre-/post-NAC TILs levels. RCB and Neo-Bioscore were significantly associated to disease-free and overall survival in global population and for triple-negative BC. RCB had the lowest AICs in every BC subtype, corresponding to a better prognostic performance. In global population, C-Index values were poor for RCB (0.66; CI [0.61-0.71]) and fair for Neo-Bioscore (0.70; CI [0.65-0.75]). Scores were well calibrated in global population, but RCB yielded better prognostic performances in each BC subtype. Concordance between the two scores was poor. Adding LVI and TILs improved the performance of both scores. Although RCB and Neo-Bioscore had similar prognostic performances, RCB showed better performance in BC subtypes, especially in luminal and TNBC. By generating fewer prognostic categories, RCB enables an easier use in everyday clinical practice.</description><subject>Antineoplastic Agents - therapeutic use</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Breast Neoplasms - pathology</subject><subject>Chemotherapy</subject><subject>Female</subject><subject>Humans</subject><subject>Invasiveness</subject><subject>Medical prognosis</subject><subject>Middle Aged</subject><subject>Neoadjuvant Therapy - methods</subject><subject>Neoplasm Staging</subject><subject>Neoplasm, Residual</subject><subject>Population</subject><subject>Prognosis</subject><subject>Survival Analysis</subject><subject>Treatment Outcome</subject><issn>0007-0920</issn><issn>1532-1827</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNpdkU1rHSEUhiW0JLdp_0AWQegmXdj4MTOOXQRybz8htBDatXj1TK6XGZ3oTCD7_vCaThraLkTE5zz4-iJ0wuhbRkV7nitWsYZQTgllvGZEHKAVqwUnrOXyGVpRSiWhitMj9CLnfTkq2spDdCREXbeSsRX6-R4mSIMPZvIx4NjhbQKTJ2xNsJDwmOJNiNlnbLoC4gDRuP18Z0JBdjDEaQfJjPfvsI3DaJLPi-Uasnez6fFm8azn5CDgs-vN-g02weGvEMnax2xjgpfoeWf6DK8e92P04-OH75vP5Orbpy-byytiK0EnUgvJJIjGWld3fEuVLfk7KxpJO7UtyzXc1sq5rlUguTBMOmdaKiqwXDaVOEYXi3ectwM4C2FKptdj8oNJ9zoar_-9CX6nb-KdLg5VNEVw9ihI8XaGPOnBZwt9b8q_zFnzqpWyUkrIgr7-D93HOYUST5eqqCoQ44XiC2VTzDlB9_QYRvVDyXopWZeS9e-StShDp3_HeBr506r4BZSOpGU</recordid><startdate>20210412</startdate><enddate>20210412</enddate><creator>Laas, Enora</creator><creator>Labrosse, Julie</creator><creator>Hamy, Anne-Sophie</creator><creator>Benchimol, Gabriel</creator><creator>de Croze, Diane</creator><creator>Feron, Jean-Guillaume</creator><creator>Coussy, Florence</creator><creator>Balezeau, Thomas</creator><creator>Guerin, Julien</creator><creator>Lae, Marick</creator><creator>Pierga, Jean-Yves</creator><creator>Reyal, Fabien</creator><general>Nature Publishing Group</general><general>Nature Publishing Group UK</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TO</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-9416-5601</orcidid><orcidid>https://orcid.org/0000-0002-2318-3589</orcidid></search><sort><creationdate>20210412</creationdate><title>Determination of breast cancer prognosis after neoadjuvant chemotherapy: comparison of Residual Cancer Burden (RCB) and Neo-Bioscore</title><author>Laas, Enora ; Labrosse, Julie ; Hamy, Anne-Sophie ; Benchimol, Gabriel ; de Croze, Diane ; Feron, Jean-Guillaume ; Coussy, Florence ; Balezeau, Thomas ; Guerin, Julien ; Lae, Marick ; Pierga, Jean-Yves ; Reyal, Fabien</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c430t-53717e36ccd5f2b09c141fc3670f9b0f9d62c59ddf89e723a17dda8034ec27643</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Antineoplastic Agents - therapeutic use</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Breast Neoplasms - pathology</topic><topic>Chemotherapy</topic><topic>Female</topic><topic>Humans</topic><topic>Invasiveness</topic><topic>Medical prognosis</topic><topic>Middle Aged</topic><topic>Neoadjuvant Therapy - methods</topic><topic>Neoplasm Staging</topic><topic>Neoplasm, Residual</topic><topic>Population</topic><topic>Prognosis</topic><topic>Survival Analysis</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Laas, Enora</creatorcontrib><creatorcontrib>Labrosse, Julie</creatorcontrib><creatorcontrib>Hamy, Anne-Sophie</creatorcontrib><creatorcontrib>Benchimol, Gabriel</creatorcontrib><creatorcontrib>de Croze, Diane</creatorcontrib><creatorcontrib>Feron, Jean-Guillaume</creatorcontrib><creatorcontrib>Coussy, Florence</creatorcontrib><creatorcontrib>Balezeau, Thomas</creatorcontrib><creatorcontrib>Guerin, Julien</creatorcontrib><creatorcontrib>Lae, Marick</creatorcontrib><creatorcontrib>Pierga, Jean-Yves</creatorcontrib><creatorcontrib>Reyal, Fabien</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Nursing and Allied Health Journals</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>ProQuest Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Biological Sciences</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Biological Science Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British journal of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Laas, Enora</au><au>Labrosse, Julie</au><au>Hamy, Anne-Sophie</au><au>Benchimol, Gabriel</au><au>de Croze, Diane</au><au>Feron, Jean-Guillaume</au><au>Coussy, Florence</au><au>Balezeau, Thomas</au><au>Guerin, Julien</au><au>Lae, Marick</au><au>Pierga, Jean-Yves</au><au>Reyal, Fabien</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Determination of breast cancer prognosis after neoadjuvant chemotherapy: comparison of Residual Cancer Burden (RCB) and Neo-Bioscore</atitle><jtitle>British journal of cancer</jtitle><addtitle>Br J Cancer</addtitle><date>2021-04-12</date><risdate>2021</risdate><volume>124</volume><issue>8</issue><spage>1421</spage><epage>1427</epage><pages>1421-1427</pages><issn>0007-0920</issn><eissn>1532-1827</eissn><notes>ObjectType-Article-2</notes><notes>SourceType-Scholarly Journals-1</notes><notes>ObjectType-Feature-1</notes><notes>content type line 23</notes><abstract>To compare RCB (Residual Cancer Burden) and Neo-Bioscore in terms of prognostic performance and see if adding pathological variables improve these scores. We analysed 750 female patients with invasive breast cancer (BC) treated with neoadjuvant chemotherapy (NAC) at Institut Curie between 2002 and 2012. Scores were compared in global population and by BC subtype using Akaike information criterion (AIC), C-Index (concordance index), calibration curves and after adding lymphovascular invasion (LVI) and pre-/post-NAC TILs levels. RCB and Neo-Bioscore were significantly associated to disease-free and overall survival in global population and for triple-negative BC. RCB had the lowest AICs in every BC subtype, corresponding to a better prognostic performance. In global population, C-Index values were poor for RCB (0.66; CI [0.61-0.71]) and fair for Neo-Bioscore (0.70; CI [0.65-0.75]). Scores were well calibrated in global population, but RCB yielded better prognostic performances in each BC subtype. Concordance between the two scores was poor. Adding LVI and TILs improved the performance of both scores. Although RCB and Neo-Bioscore had similar prognostic performances, RCB showed better performance in BC subtypes, especially in luminal and TNBC. By generating fewer prognostic categories, RCB enables an easier use in everyday clinical practice.</abstract><cop>England</cop><pub>Nature Publishing Group</pub><pmid>33558711</pmid><doi>10.1038/s41416-020-01251-3</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0002-9416-5601</orcidid><orcidid>https://orcid.org/0000-0002-2318-3589</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0007-0920
ispartof British journal of cancer, 2021-04, Vol.124 (8), p.1421-1427
issn 0007-0920
1532-1827
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8039034
source PubMed (Medline); Springer Link
subjects Antineoplastic Agents - therapeutic use
Breast cancer
Breast Neoplasms - drug therapy
Breast Neoplasms - pathology
Chemotherapy
Female
Humans
Invasiveness
Medical prognosis
Middle Aged
Neoadjuvant Therapy - methods
Neoplasm Staging
Neoplasm, Residual
Population
Prognosis
Survival Analysis
Treatment Outcome
title Determination of breast cancer prognosis after neoadjuvant chemotherapy: comparison of Residual Cancer Burden (RCB) and Neo-Bioscore
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-23T02%3A32%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Determination%20of%20breast%20cancer%20prognosis%20after%20neoadjuvant%20chemotherapy:%20comparison%20of%20Residual%20Cancer%20Burden%20(RCB)%20and%20Neo-Bioscore&rft.jtitle=British%20journal%20of%20cancer&rft.au=Laas,%20Enora&rft.date=2021-04-12&rft.volume=124&rft.issue=8&rft.spage=1421&rft.epage=1427&rft.pages=1421-1427&rft.issn=0007-0920&rft.eissn=1532-1827&rft_id=info:doi/10.1038/s41416-020-01251-3&rft_dat=%3Cproquest_pubme%3E2510999312%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c430t-53717e36ccd5f2b09c141fc3670f9b0f9d62c59ddf89e723a17dda8034ec27643%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2510999312&rft_id=info:pmid/33558711&rfr_iscdi=true